Xizang Haisco Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Xizang Haisco Pharmaceutical Group Co Ltd (002653.CS)

Q3 20268 Jul – 26 Aug 2026

▲4

Haisco's profit surge and new licensing deals drive gains

First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.
This is the core earnings catalyst that directly explains the stock's positive momentum.
New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.
This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.
New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.
This is a fresh, material deal that directly adds near-term cash and potential long-term value.
Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.
It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

August 20268 Jul – 26 Aug 2026

▲4

Haisco's profit surge and new licensing deals drive gains

First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.
This is the core earnings catalyst that directly explains the stock's positive momentum.
New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.
This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.
New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.
This is a fresh, material deal that directly adds near-term cash and potential long-term value.
Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.
It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

Latest8 Jul – 26 Aug 2026

▲4

Haisco's profit surge and new licensing deals drive gains

First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.
This is the core earnings catalyst that directly explains the stock's positive momentum.
New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.
This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.
New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.
This is a fresh, material deal that directly adds near-term cash and potential long-term value.
Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.
It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

August 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

Latest31 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.